 | Up a level |
Fuchs, Michael; Jacob, Anne Sophie; Kaul, Helen; Kobe, Carsten; Kuhnert, Georg; Pabst, Thomas; Greil, Richard; Bröckelmann, Paul J; Topp, Max S; Just, Marianne; Hertenstein, Bernd; Soekler, Martin; Vogelhuber, Martin; Zijlstra, Josée M; Keller, Ulrich Bernd; Krause, Stefan W; Dührsen, Ulrich; Meissner, Julia; Viardot, Andreas; Eich, Hans-Theodor; ... (2024). Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Leukemia, 38(1), pp. 160-167. Springer Nature 10.1038/s41375-023-02064-y
Kreissl, Stefanie; Voltin, Conrad‐Amadeus; Kaul, Helen; Bühnen, Ina; Mettler, Jasmin; Pabst, Thomas; Eichenauer, Dennis A.; Fuchs, Michael; Diehl, Volker; Dietlein, Markus; Engert, Andreas; Borchmann, Peter; Kobe, Carsten (2022). Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma. British journal of haematology, 197(1), e5-e8. Wiley-Blackwell 10.1111/bjh.17997
Kreissl, Stefanie; Goergen, Helen; Buehnen, Ina; Kobe, Carsten; Moccia, Alden; Greil, Richard; Eichenauer, Dennis A; Zijlstra, Josée M; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Soekler, Martin; Beck, Hans-Joachim; Willenbacher, Wolfgang; Ludwig, Wolf-Dieter; Pabst, Thomas; Topp, Max S; Hitz, Felicitas; Bentz, Martin; Keller, Ulrich Bernd; ... (2021). PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. The Lancet. Haematology, 8(6), e398-e409. Elsevier 10.1016/S2352-3026(21)00101-0
Borchmann, Peter; Plütschow, Annette; Kobe, Carsten; Greil, Richard; Meissner, Julia; Topp, Max S; Ostermann, Helmut; Dierlamm, Judith; Mohm, Johannes; Thiemer, Julia; Sökler, Martin; Kerkhoff, Andrea; Ahlborn, Miriam; Halbsguth, Teresa V; Martin, Sonja; Keller, Ulrich; Balabanov, Stefan; Pabst, Thomas; Vogelhuber, Martin; Hüttmann, Andreas; ... (2021). PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. The lancet oncology, 22(2), pp. 223-234. Elsevier 10.1016/S1470-2045(20)30601-X
Mettler, Jasmin; Müller, Horst; Voltin, Conrad-Amadeus; Baues, Christian; Klaeser, Bernd; Moccia, Alden; Borchmann, Peter; Engert, Andreas; Kuhnert, Georg; Drzezga, Alexander; Dietlein, Markus; Kobe, Carsten (2019). Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma. Journal of nuclear medicine, 60(2), pp. 207-211. Society of Nuclear Medicine 10.2967/jnumed.118.210047
Borchmann, Peter; Goergen, Helen; Kobe, Carsten; Lohri, Andreas; Greil, Richard; Eichenauer, Dennis A; Zijlstra, Josée M; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Hüttmann, Andreas; Dierlamm, Judith; Soekler, Martin; Beck, Hans-Joachim; Willenbacher, Wolfgang; Ludwig, Wolf-Dieter; Pabst Müller, Thomas Niklaus; Topp, Max S; Hitz, Felicitas; Bentz, Martin; ... (2018). PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, 390(10114), pp. 2790-2802. Elsevier 10.1016/S0140-6736(17)32134-7
